Company intelligence / Profile preview
Akouos
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
Overview
Akouos’s lead program, AK-OTOF, is an AAV-based gene therapy targeting sensorineural hearing loss caused by mutations in the otoferlin gene. The program is currently in Phase 2 clinical trials. Preclinical data have shown promise for restoring physiologic hearing following a single administration to the inner ear. Additional programs are at preclinical or discovery stages targeting other forms of genetic hearing loss and related indications such as Usher syndrome and acoustic neuroma.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Gene therapyAdeno-associated viral (AAV) vector-based gene therapy
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Akouos.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akouos.